• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
PVP-K30-----pharma excipients(CAS No.9003-39-8)
Tobramycin
Povidone iodine 20% powder
Povidone iodine 10% powder
SULBACTAM SODIUM STERILE
Food Additives Bulk Sucralose Neotame Advantame Powder

Rare disease biotech Rallybio sets terms for $81 million IPO

firstwordpharmaJuly 23, 2021

Tag: Rallybio , IPO , RLYB211

Rallybio plans to raise $81 million in its initial public offering by offering 5.8 million shares at a price range of $13 to $15, as reported by NASDAQ.

The company is currently advancing its lead program, RLYB211, in a Phase I/II trial for the treatment of fetal and neonatal alloimmune thrombocytopenia (FNAIT).

RLYB211 is a polyclonal anti-HPA-1a antibody and is expected to report data from its Phase I/II trial this month.

The company also has four preclinical programs, one of which, RLBY212, is also being developed for the treatment of FNAIT, and two of which are being developed to treat complement dysregulation diseases.


Previous:TGA approves Pfizer COVID-19 vaccine for 12 to 15-year-olds

Next:Acticor Biotech Announces the Completion of Enrollment in its GARDEN Clinical Trial, a COVID-19-induced Acute Respiratory Distress Syndrome Efficacy Study

Related News

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

PharmaSourcesSeptember 19, 2024

InnoCare Pharma announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China.

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

PharmaSourcesSeptember 18, 2024

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

PharmaSourcesSeptember 14, 2024

Rare disease biotech Rallybio sets terms for $81 million IPO | Pharmasources.com

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

Biotech NewswireAugust 28, 2024

Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk.

You may like
More>>

α-Lipoic acid

α-Lipoic acid
(24R,24′R)-bis-Calcipotriol ether

(24R,24′R)-bis-Calcipotriol ether
Calcipotriol

Calcipotriol

Alpha lipoic acid

Alpha lipoic acid
COLESTIPOL HYDROCHLORIDE

COLESTIPOL HYDROCHLORIDE
PuriActives® Liposomal MSH

PuriActives® Liposomal MSH
Calcipotriene

Calcipotriene
PuriActives® Nanoliposomal AGE

PuriActives® Nanoliposomal AGE
toc tipos

toc tipos
alpha lipoic acid

alpha lipoic acid

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service